Glimulin MV 1 Tablet ER
Glimulin MV 1 Tablet ER
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Cheaper alternative availability
Already at the Best Price
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
About This Medicine
Product description & overview
Glimulin MV 1 Tablet ER is a combination oral hypoglycemic agent formulated for the management of type 2 diabetes mellitus. Each extended-release tablet contains Glimepiride 1 mg, Metformin 500 mg, and Voglibose 0.2 mg, providing a multifaceted approach to glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, thereby reducing insulin resistance. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, mitigating postprandial hyperglycemia. The extended-release formulation ensures sustained plasma drug levels, promoting improved patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Glimulin MV 1 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled by monotherapy. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and hypersensitivity to any component. Regular monitoring of blood glucose and renal function is recommended during therapy. This combination therapy offers a comprehensive mechanism to address fasting and postprandial blood glucose levels, contributing to overall metabolic control and reducing the risk of diabetes-related complications.
Active composition
Glimepiride 1 mg
+2 more active ingredients
About Glimepiride
Glimepiride is an oral hypoglycemic agent used to manage blood sugar levels in patients with type 2 diabetes mellitus. It works by stimulating the pancreas to release more insulin, thereby lowering blood glucose levels and preventing the symptoms associated with diabetes. Glimepiride is often prescribed alongside diet and exercise to enhance glycemic control and reduce the risk of diabetes-related complications, such as kidney damage and neuropathy. In summary, Glimepiride is an essential medication for controlling blood sugar levels in type 2 diabetes patients.
How It Works
Glimepiride stimulates insulin secretion from pancreatic beta cells and enhances insulin sensitivity in peripheral tissues, facilitating glucose uptake and lowering blood sugar levels.
All Active Ingredients
Voglibose
Voglibose inhibits intestinal alpha-glucosidases, delaying carbohydrate digestion and absorption, thus lowering postprandial glucose levels.
Metformin
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Dosage & How to Use
Dosage information not available. Please consult your doctor or pharmacist.
Safety Advice
Important precautions
Side Effect Occurrence
Based on clinical trials and patient reports.
Overall Tolerance
Most patients tolerate well
Common Side Effects
Safety Advice
Alcohol
It is unsafe to consume alcohol with Glimulin MV 1 Tablet ER.
High Risk
Pregnancy
Glimulin MV 1 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Medical Advice
Driving
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Exercise Caution
Liver
Glimulin MV 1 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Glimulin MV 1 Tablet ER may be needed. Please consult your doctor. Glimulin MV 1 Tablet ER is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.
Regular Checkup
Breastfeeding
Glimulin MV 1 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Consult Doctor
Kidney
Glimulin MV 1 Tablet ER is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor. Use of Glimulin MV 1 Tablet ER is, however, not recommended in patients with severe kidney disease.
Regular Checkup
Customer Reviews
0 reviews for Glimulin MV 1 Tablet ER
